The role of gut microbiome and fecal microbiota transplantation in liver cancer and related complications: mechanisms and therapeutic potentials

Abstract

Liver cancer is the sixth commonest cancer and the third leading cause of cancer mortality worldwide. Accumulating evidence suggests a pivotal role of the gut microbiome in the progression of chronic liver disease and the subsequent development of liver cancer. Additionally, gut microbiome has been shown to contribute to the hosts’ antitumor responses following immunotherapy and chemotherapy for liver cancers, highlighting the therapeutic potential of gut microbiome modulation in enhancing treatment efficacy and reducing drug resistance. Fecal microbiota transplantation (FMT), a novel therapeutic modality to deliver a healthy donor's stool by endoscopy or capsule, has demonstrated potential in managing liver diseases and cancers by restoring and modulating the recipient’s gut microbiome composition. However, existing data on the clinical application of FMT in liver cancers are still limited. This review summarizes the underlying roles and mechanisms of gut microbiome in liver cancer and discusses the therapeutic potential of FMT in liver cancer treatment and the management of its related complications (e.g., hepatic encephalopathy).

Keywords

Liver cancer / hepatocellular cancer / hepatic encephalopathy / gut microbiome / fecal microbiota transplantation

References

[1] Sung H,Siegel RL.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[2] McGlynn KA,London WT.Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability.Clin Liver Dis2015;19:223-38 PMCID:PMC4712629

[3] Tripathi A,Brenner DA.The gut-liver axis and the intersection with the microbiome.Nat Rev Gastroenterol Hepatol2018;15:397-411.

[4] Yu LX.The gut microbiome and liver cancer: mechanisms and clinical translation.Nat Rev Gastroenterol Hepatol2017;14:527-39 PMCID:PMC6467288

[5] Gupta A.Fecal microbiota transplantation.JAMA2017;318:102

[6] Peng Z,He Z.Colonic transendoscopic enteral tubing: a novel way of transplanting fecal microbiota.Endosc Int Open2016;4:E610-3 PMCID:PMC4993903

[7] Wang W,Wu X,Zhang F.Colonic transendoscopic enteral tubing is a new pathway to microbial therapy, colonic drainage, and host-microbiota interaction research.J Clin Med2023;12:780 PMCID:PMC9918197

[8] van Nood E,Nieuwdorp M.Duodenal infusion of donor feces for recurrent Clostridium difficile.N Engl J Med2013;368:407-15

[9] Johnson S,Skinner AM.Clinical practice guideline by the infectious diseases society of America (IDSA) and society for healthcare epidemiology of America (SHEA): 2021 focused update guidelines on management of clostridioides difficile infection in adults.Clin Infect Dis2021;73:755-7

[10] Mullish BH,Segal JP.The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines.Gut2018;67:1920-41

[11] Prehn J, Reigadas E, Vogelzang EH, et al; Guideline Committee of the European Study Group on Clostridioides difficile. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults.Clin Microbiol Infect2021;27 Suppl 2:S1-S21.

[12] Xue L,Luo W,Chen Y.Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial.Front Cell Infect Microbiol2022;12:759306 PMCID:PMC9289257

[13] Craven L,Nair Parvathy S.Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial.Am J Gastroenterol2020;115:1055-65.

[14] Chauhan A,Sharma S.Fecal microbiota transplantation in hepatitis B e antigen-positive chronic hepatitis b patients: a pilot study.Dig Dis Sci2021;66:873-80.

[15] Bajaj JS,Fagan A.Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial.Hepatology2017;66:1354-5

[16] Bajaj JS,Acharya C.Fecal microbial transplant capsules are safe in hepatic encephalopathy: a phase 1, randomized, placebo-controlled trial.Hepatology2019;70:1690-703 PMCID:PMC6819208

[17] Cabrera R.Review article: the management of hepatocellular carcinoma.Aliment Pharmacol Ther2010;31:461-76

[18] El-Serag HB.Hepatocellular carcinoma.N Engl J Med2011;365:1118-27.

[19] Schwabe RF.Gut microbiome in HCC-mechanisms, diagnosis and therapy.J Hepatol2020;72:230-8

[20] Zhang HL,Yang W.Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats.J Hepatol2012;57:803-12

[21] Das BK.Altered gut microbiota in hepatocellular carcinoma: Insights into the pathogenic mechanism and preclinical to clinical findings.APMIS2022;130:719-40.

[22] Ni J,Zhou H.Analysis of the relationship between the degree of dysbiosis in gut microbiota and prognosis at different stages of primary hepatocellular carcinoma.Front Microbiol2019;10:1458 PMCID:PMC6603198

[23] Deng T,He B.Gut microbiome alteration as a diagnostic tool and associated with inflammatory response marker in primary liver cancer.Hepatol Int2022;16:99-111

[24] Lai MW,Hsu CW,Liang KH.Multi-omics analyses identify signatures in patients with liver cirrhosis and hepatocellular carcinoma.Cancers2022;15:210 PMCID:PMC9818216

[25] Liu B,Jin Y.Hepatic stellate cell activation and senescence induced by intrahepatic microbiota disturbances drive progression of liver cirrhosis toward hepatocellular carcinoma.J Immunother Cancer2022;10:e003069 PMCID:PMC8744134

[26] Chen T,Chen X.Firmicutes and blautia in gut microbiota lessened in chronic liver diseases and hepatocellular carcinoma patients: a pilot study.Bioengineered2021;12:8233-46 PMCID:PMC8806631

[27] Lapidot Y,Nosenko R.Alterations in the gut microbiome in the progression of cirrhosis to hepatocellular carcinoma.mSystems2020;5:e00153-20 PMCID:PMC7300357

[28] Ren Z,Jiang J.Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma.Gut2019;68:1014-23. PMCID:PMC6580753

[29] Liu Q,Zhuang Y.Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma.Gut Pathog2019;11:1. PMCID:PMC6337822

[30] Jia X,Zeng Z.Characterization of gut microbiota, bile acid metabolism, and cytokines in intrahepatic cholangiocarcinoma.Hepatology2020;71:893-906.

[31] Saab M,Sohrabi M.Characterization of biliary microbiota dysbiosis in extrahepatic cholangiocarcinoma.PLoS One2021;16:e0247798. PMCID:PMC7943025

[32] Rao BC,Zou YW.Alterations in the human oral microbiome in cholangiocarcinoma.Mil Med Res2022;9:62 PMCID:PMC9641929

[33] Chen B,Lu L.A preliminary study of biliary microbiota in patients with bile duct stones or distal cholangiocarcinoma.Biomed Res Int2019;2019:1092563. PMCID:PMC6778921

[34] Pujic P,Ravalison M,Rodríguez-nava V.Nocardia and actinomyces. Molecular medical microbiology. Elsevier; 2015. pp. 731-52.

[35] Zhang Q,Duan Y.Gut microbiome directs hepatocytes to recruit MDSCs and promote cholangiocarcinoma.Cancer Discov2021;11:1248-67 PMCID:PMC8102309

[36] Bajaj JS,Hylemon PB.Altered profile of human gut microbiome is associated with cirrhosis and its complications.J Hepatol2014;60:940-7. PMCID:PMC3995845

[37] Shen F,Sun XQ,Wang XY.Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease.Hepatobiliary Pancreat Dis Int2017;16:375-81

[38] Fox JG,Theve EJ.Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens.Gut2010;59:88-97. PMCID:PMC3891362

[39] Dapito DH,Gwak GY.Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4.Cancer Cell2012;21:504-16 PMCID:PMC3332000

[40] Yoshimoto S,Atarashi K.Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome.Nature2013;499:97-101.

[41] Zhang X,Chu ES.Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.Gut2021;70:761-74. PMCID:PMC7948195

[42] Petrick JL,Znaor A.International trends in hepatocellular carcinoma incidence, 1978-2012.Int J Cancer2020;147:317-30 PMCID:PMC7470451

[43] Yeh SH.Gender disparity of hepatocellular carcinoma: the roles of sex hormones.Oncology2010;78 Suppl 1:172-9

[44] Nevola R,Rosato V.Gender differences in the pathogenesis and risk factors of hepatocellular carcinoma.Biology2023;12:984 PMCID:PMC10376683

[45] Kalra M,Assefa S,Kaul R.Role of sex steroid receptors in pathobiology of hepatocellular carcinoma.World J Gastroenterol2008;14:5945-61. PMCID:PMC2760195

[46] Markle JG,Mortin-Toth S.Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity.Science2013;339:1084-8.

[47] Yurkovetskiy L,Khan AA.Gender bias in autoimmunity is influenced by microbiota.Immunity2013;39:400-12 PMCID:PMC3822899

[48] Ridlon JM,Alves JM.Clostridium scindens: a human gut microbe with a high potential to convert glucocorticoids into androgens.J Lipid Res2013;54:2437-49 PMCID:PMC3735941

[49] Xie G,Zhao A.Sex-dependent effects on gut microbiota regulate hepatic carcinogenic outcomes.Sci Rep2017;7:45232 PMCID:PMC5366919

[50] Zhou J,Sinha RA,Yen PM.Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease.Hepatoma Res2021;7:11 PMCID:PMC7116620

[51] Sousa P.MAFLD under the lens: the role of gut microbiota.Metab Target Organ Damage2022;2:14

[52] Huang R,Ni J.Different sex-based responses of gut microbiota during the development of hepatocellular carcinoma in liver-specific Tsc1-knockout mice.Front Microbiol2018;9:1008 PMCID:PMC5964185

[53] Fattovich G,Zagni I.Hepatocellular carcinoma in cirrhosis: incidence and risk factors.Gastroenterology2004;127:S35-50

[54] Meriggi F.Clinical characterisation and management of the main treatment-induced toxicities in patients with hepatocellular carcinoma and cirrhosis.Cancers2021;13:584 PMCID:PMC7867371

[55] Chen Y,Lu H.Characterization of fecal microbial communities in patients with liver cirrhosis.Hepatology2011;54:562-72

[56] Bajaj JS,White MB.Specific gut and salivary microbiota patterns are linked with different cognitive testing strategies in minimal hepatic encephalopathy.Am J Gastroenterol2019;114:1080-90 PMCID:PMC6610654

[57] Bajaj JS,Fagan A.Distinct gut microbial compositional and functional changes associated with impaired inhibitory control in patients with cirrhosis.Gut Microbes2021;13:1953247 PMCID:PMC8344770

[58] Bajaj JS,Hylemon PB.Linkage of gut microbiome with cognition in hepatic encephalopathy.Am J Physiol Gastrointest Liver Physiol2012;302:G168-75 PMCID:PMC3345956

[59] Ho AHY,Lui R.Topic: nutrition and the gut-liver-brain axis.Curr Hepatology Rep2022;21:99-110

[60] Jackson R,Berhane S,Johnson P.Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer: a meta-analysis of randomized phase III trials.J Clin Oncol2017;35:622-8

[61] Kudo M,Qin S.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.Lancet2018;391:1163-73

[62] El-Serag HB,Rudolph L.Diagnosis and treatment of hepatocellular carcinoma.Gastroenterology2008;134:1752-63

[63] Finn RS,Ikeda M.IMbrave150 InvestigatorsAtezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.N Engl J Med2020;382:1894-905

[64] Abou-alfa GK,Kudo M.Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.NEJM Evidence2022;1:EVIDoa2100070

[65] Yau T,Kim TY.Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the checkmate 040 randomized clinical trial.JAMA Oncol2020;6:e204564 PMCID:PMC7530824

[66] Finn RS,Zhu AX.Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma.J Clin Oncol2020;38:2960-70. PMCID:PMC7479760

[67] Alexander JL,Teare J,Nicholson JK.Gut microbiota modulation of chemotherapy efficacy and toxicity.Nat Rev Gastroenterol Hepatol2017;14:356-65

[68] Jin M,Han Y.Gut microbiota enhances the chemosensitivity of hepatocellular carcinoma to 5-fluorouracil in vivo by increasing curcumin bioavailability.Phytother Res2021;35:5823-37

[69] Inukai Y,Honda T.Differences in the intestinal microbiome associated with diarrhea during lenvatinib treatment for hepatocellular carcinoma.Dig Dis2023;41:138-47 PMCID:PMC9909711

[70] Yamamoto K,Honda T.Relationship between adverse events and microbiomes in advanced hepatocellular carcinoma patients treated with sorafenib.Anticancer Res2020;40:665-76

[71] El-Khoueiry AB,Yau T.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.Lancet2017;389:2492-502 PMCID:PMC7539326

[72] Zhu AX,Edeline J.KEYNOTE-224 investigatorsPembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.Lancet Oncol2018;19:940-52

[73] Zheng Y,Tu X.Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma.J Immunother Cancer2019;7:193 PMCID:PMC6651993

[74] Chung MW,Won EJ.Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients.World J Gastroenterol2021;27:7340-9 PMCID:PMC8611200

[75] Wu H,Pan T.Dynamic microbiome and metabolome analyses reveal the interaction between gut microbiota and anti-PD-1 based immunotherapy in hepatocellular carcinoma.Int J Cancer2022;151:1321-34

[76] Routy B,Derosa L.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.Science2018;359:91-7

[77] Davar D,McCulloch JA.Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients.Science2021;371:595-602 PMCID:PMC8097968

[78] Lee PC,Hung YW.Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.J Immunother Cancer2022;10:e004779 PMCID:PMC9226985

[79] Finn RS,Merle P.KEYNOTE-240 investigatorsPembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial.J Clin Oncol2020;38:193-202.

[80] Kelley RK,Harris W.Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I/II study.J Clin Oncol2021;39:2991-3001. PMCID:PMC8445563

[81] Yau T,Finn R.CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs. sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC).Annals of Oncology2019;30:v874-5

[82] Abou-alfa GK,Kudo M.Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.J Clin Oncol2022;40:379

[83] Costante F,Santopaolo F,Pompili M.Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: lights and shadows.World J Gastrointest Oncol2022;14:1622-36 PMCID:PMC9516656

[84] Li Z,Hong W.Gut microbiota modulate radiotherapy-associated antitumor immune responses against hepatocellular carcinoma via STING signaling.Gut Microbes2022;14:2119055 PMCID:PMC9467592

[85] McIlwain DR,Maretzky T.iRhom2 regulation of TACE controls TNF-mediated protection against Listeria and responses to LPS.Science2012;335:229-32 PMCID:PMC4250273

[86] Bian CF,Yu A.Gut microbiota changes and biological mechanism in hepatocellular carcinoma after transarterial chemoembolization treatment.Front Oncol2022;12:1002589 PMCID:PMC9577458

[87] Gulati M,Corrie L,Chandwani L.Delivery routes for faecal microbiota transplants: available, anticipated and aspired.Pharmacol Res2020;159:104954

[88] Baxter M,Colville A.Fatal aspiration pneumonia as a complication of fecal microbiota transplant.Clin Infect Dis2015;61:136-7.

[89] Kelly CR,Staley C.Effect of fecal microbiota transplantation on recurrence in multiply recurrent clostridium difficile infection: a randomized trial.Ann Intern Med2016;165:609-16 PMCID:PMC5909820

[90] Kao D,Silva M.Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent clostridium difficile infection: a randomized clinical trial.JAMA2017;318:1985-93 PMCID:PMC5820695

[91] Bloom PP,Torres Soto M,Hohmann E.Fecal microbiota transplant improves cognition in hepatic encephalopathy and its effect varies by donor and recipient.Hepatol Commun2022;6:2079-89 PMCID:PMC9315114

[92] Hvas CL,Jørgensen SP.Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent clostridium difficile infection.Gastroenterology2019;156:1324-1332.e3

[93] Juul FE,Bretthauer M.Fecal microbiota transplantation for primary clostridium difficile infection.N Engl J Med2018;378:2535-6

[94] Haifer C,Kaakoush NO.Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial.Lancet Gastroenterol Hepatol2022;7:141-51

[95] Sokol H,Seksik P.Saint-Antoine IBD NetworkFecal microbiota transplantation to maintain remission in Crohn's disease: a pilot randomized controlled study.Microbiome2020;8:12 PMCID:PMC6998149

[96] Costello SP,Waters O.Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial.JAMA2019;321:156-64 PMCID:PMC6439766

[97] Wang H,Li Q.The safety of fecal microbiota transplantation for Crohn's disease: findings from a long-term study.Adv Ther2018;35:1935-44 PMCID:PMC6223988

[98] Paramsothy S,Kaakoush NO.Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial.Lancet2017;389:1218-28

[99] Baruch EN,Ben-Betzalel G.Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.Science2021;371:602-9.

[100] Ianiro G,Thomas AM.Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma.Nat Commun2020;11:4333 PMCID:PMC7455693

[101] Kakihana K,Suda W.Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut.Blood2016;128:2083-8. PMCID:PMC5085256

[102] Zhao Y,Zhou Y.Safety and efficacy of fecal microbiota transplantation for grade IV steroid refractory GI-GvHD patients: interim results from FMT2017002 trial.Front Immunol2021;12:678476 PMCID:PMC8248496

[103] Dai M,Chen W.Rescue fecal microbiota transplantation for antibiotic-associated diarrhea in critically ill patients.Crit Care2019;23:324 PMCID:PMC6805332

[104] Ding X,Li P.Long-term safety and efficacy of fecal microbiota transplant in active ulcerative colitis.Drug Saf2019;42:869-80

[105] Zhang T,Zhao Z.Washed microbiota transplantation vs. manual fecal microbiota transplantation: clinical findings, animal studies and in vitro screening.Protein Cell2020;11:251-66 PMCID:PMC7093410

[106] Lu G,Li P,Cui B.Washed preparation of faecal microbiota changes the transplantation related safety, quantitative method and delivery.Microb Biotechnol2022;15:2439-49 PMCID:PMC9437882

[107] Xiang Z,Li J,Wei X.Gut microbiota modulation: a viable strategy to address medical needs in hepatocellular carcinoma and liver transplantation.Engineering2023;online ahead of print

[108] Shen YC,Kuo YL.An exploratory study for the association of gut microbiome with efficacy of immune checkpoint inhibitor in patients with hepatocellular carcinoma.J Hepatocell Carcinoma2021;8:809-22 PMCID:PMC8318216

[109] Mao J,Long J.Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers.J Immunother Cancer2021;9:e003334

[110] Sharma A,Premkumar M.Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an openlabel clinical trial.Hepatol Int2022;16:433-46

[111] Huang HC,Chang CC.Microbiota transplants from feces or gut content attenuated portal hypertension and portosystemic collaterals in cirrhotic rats.Clin Sci2021;135:2709-28